Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionWalleye Trading LLC
Latest Disclosed Ownership5,756 shares
Latest Disclosed Value $ 1,904,488
Walleye Trading LLC ownership in DUL / Alnylam Pharmaceuticals, Inc.

On May 8, 2026 - Walleye Trading LLC filed a 13F-HR form disclosing ownership of 5,756 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $1,644,489 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 8,657 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -33.51% during the quarter. The current value of the position is $1,499,438 USD.

Walleye Trading LLC has a history of taking positions in derivatives of the underlying security (DUL) in the form of stock options. The firm currently holds call options representing 100 of underlying shares valued at $33,087 USD and put options representing 6,600 of underlying shares valued at $2,183,742 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:DUL / Alnylam Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,756 -2,901 -33.51 1,904 -44.68 0.0032
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,657 7,062 442.76 3,442 373.45 0.0049
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,595 1,252 365.01 727 554.95 0.0011
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 343 -3,017 -89.79 112 -87.76 0.0002
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,360 3,360 907 0.0021
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,318 -100.00 0 -100.00
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,318 -23,854 -94.76 320 -91.49 0.0008
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,172 2,661 11.82 3,762 -12.70 0.0080
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 22,511 22,511 4,309 0.0093
2023-11-21 2023-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -4,489 -100.00 0 -100.00
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -4,489 0
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,489 -1,548 -25.64 853 -29.53 0.0026
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,037 6,037 1,209 0.0026
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -28,223 -100.00 0 -100.00
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,223 16,154 133.85 5,649 220.97 0.0172
2022-08-08 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,069 12,069 1,760 0.0057
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -3,305 -100.00 0 -100.00
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,305 1,705 106.56 560 85.43 0.0018
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,600 -651 -28.92 302 -20.94 0.0011
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,251 1,597 244.19 382 315.22 0.0015
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 654 -765 -53.91 92 -50.00 0.0004
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,419 1,419 184 0.0008
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -11,048 -100.00 0 -100.00
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,048 11,048 1,203 0.0093
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -2,986 -100.00 0 -100.00
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,986 -34 -1.13 240 9.59 0.0020
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,020 3,020 219 0.0019
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -5,236 -100.00 0 -100.00
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,236 -3,967 -43.11 382 -52.55 0.0028
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,203 4,589 99.46 805 77.31 0.0042
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,614 4,614 454 0.0024
2016-02-16 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -300 -100.00 0 -100.00
2015-11-16 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 300 200 200.00 24 100.00 0.0002
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 100 100 12 0.0001
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-08 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 100 -83.33 33 -86.13 n/a n/a n/a
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 600 0.00 239 -12.82 n/a n/a n/a
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 600 -66.67 274 -53.41 n/a n/a n/a
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 1,800 -48.57 587 -37.99 n/a n/a n/a
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 3,500 -37.50 945 -28.25 n/a n/a n/a
2025-02-13 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 5,600 -15.15 1,318 -27.44 n/a n/a n/a
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 6,600 46.67 1,815 66.06 n/a n/a n/a
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 4,500 -75.27 1,094 -59.80 n/a n/a n/a
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 18,200 13.75 2,720 -11.20 n/a n/a n/a
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 16,000 20.30 3,063 30.02 n/a n/a n/a
2023-11-21 2023-09-30 13F/A ALNYLAM PHARMACEUTICALS COM Call 13,300 20.91 2,355 12.73 n/a n/a n/a
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 13,300 2,355 n/a n/a n/a
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 11,000 -48.84 2,089 -51.49 n/a n/a n/a
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 21,500 12.57 4,307 -5.13 n/a n/a n/a
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 19,100 -66.67 4,539 -60.42 n/a n/a n/a
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 57,300 98.96 11,469 173.07 n/a n/a n/a
2022-08-08 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 28,800 11.63 4,200 -0.31 n/a n/a n/a
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 25,800 5,060.00 4,213 4,856.47 n/a n/a n/a
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 500 85 n/a n/a n/a
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 45,900 967.44 7,781 1,181.88 n/a n/a n/a
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 4,300 2,050.00 607 2,234.62 n/a n/a n/a
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 200 -99.28 26 -99.36 n/a n/a n/a
2020-11-16 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 27,900 304.35 4,062 297.46 n/a n/a n/a
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 6,900 -56.60 1,022 -40.96 n/a n/a n/a
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 15,900 -32.34 1,731 -36.03 n/a n/a n/a
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 23,500 459.52 2,706 700.59 n/a n/a n/a
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 4,200 600.00 338 668.18 n/a n/a n/a
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 600 -96.69 44 -97.40 n/a n/a n/a
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 18,100 311.36 1,691 426.79 n/a n/a n/a
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 4,400 109.52 321 74.46 n/a n/a n/a
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 2,100 -47.50 184 -53.30 n/a n/a n/a
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 4,000 394 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-08 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 6,600 -52.17 2,184 -60.22 n/a n/a n/a
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 13,800 89.04 5,488 64.87 n/a n/a n/a
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 7,300 630.00 3,329 920.86 n/a n/a n/a
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 1,000 -84.13 326 -80.83 n/a n/a n/a
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 6,300 270.59 1,701 325.25 n/a n/a n/a
2025-02-13 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 1,700 -67.31 400 -72.03 n/a n/a n/a
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 5,200 30.00 1,430 47.12 n/a n/a n/a
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 4,000 -95.15 972 -92.12 n/a n/a n/a
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 82,500 -14.15 12,330 -32.97 n/a n/a n/a
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 96,100 452.30 18,395 497.01 n/a n/a n/a
2023-11-21 2023-09-30 13F/A ALNYLAM PHARMACEUTICALS COM Put 17,400 -24.68 3,082 -29.77 n/a n/a n/a
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 17,400 3,082 n/a n/a n/a
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 23,100 -16.30 4,388 -20.64 n/a n/a n/a
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 27,600 -33.49 5,529 -43.95 n/a n/a n/a
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 41,500 -62.38 9,862 -55.33 n/a n/a n/a
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 110,300 49.66 22,078 105.40 n/a n/a n/a
2022-08-08 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 73,700 357.76 10,749 308.86 n/a n/a n/a
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 16,100 67.71 2,629 61.49 n/a n/a n/a
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 9,600 77.78 1,628 59.61 n/a n/a n/a
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 5,400 -81.94 1,020 -79.88 n/a n/a n/a
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 29,900 1,395.00 5,069 1,697.52 n/a n/a n/a
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 2,000 -90.24 282 -89.41 n/a n/a n/a
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 20,500 0.00 2,664 -10.75 n/a n/a n/a
2020-11-16 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 20,500 -5.53 2,985 -7.13 n/a n/a n/a
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 21,700 -44.36 3,214 -24.29 n/a n/a n/a
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 39,000 36.84 4,245 29.34 n/a n/a n/a
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 28,500 345.31 3,282 537.28 n/a n/a n/a
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 6,400 -63.64 515 -59.67 n/a n/a n/a
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 17,600 203.45 1,277 135.61 n/a n/a n/a
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 5,800 -10.77 542 14.35 n/a n/a n/a
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 6,500 209.52 474 157.61 n/a n/a n/a
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 2,100 -67.19 184 -70.79 n/a n/a n/a
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 6,400 630 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.